Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles

HIV Clinical Trials
Frederic CrouzatMona Loutfy

Abstract

The resistance profiles for patients on first-line antiretroviral therapy (ART) regimens after viremia have not been well studied in community clinic settings in the modern treatment era. To determine time to viremia and the ART resistance profiles of viremic patients. HIV-positive patients aged ≥16 years initiating a three-drug regimen were retrospectively identified from 01/01/06 to 12/31/12. The regimens were a backbone of two nucleoside reverse transcriptase inhibitors (NRTIs) and a third agent: a protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNRTI), or an integrase inhibitor (II). Time to viremia was compared using a proportional hazards model, adjusting for demographic and clinical factors. Resistance profiles were described in those with baseline and follow-up genotypes. For 653 patients, distribution of third-agent use and viremia was: 244 (37%) on PIs with 80 viremia, 364 (56%) on NNRTIs with 84 viremia, and 45 (7%) on II with 11 viremia. Only for NNRTIs, time to viremia was longer than PIs (p = 0.04) for patients with a CD4 count ≥200 cells/mm(3). Of the 175 with viremia, 143 (82%) had baseline and 37 (21%) had follow-up genotype. Upon viremia, emerging ART resistance was rare. One new NNRTI...Continue Reading

References

Dec 1, 1995·The Journal of Experimental Medicine·S I StapransM B Feinberg
Jun 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·M TisdaleB A Larder
Apr 21, 1999·Trends in Microbiology·P R Harrigan, C S Alexander
Mar 7, 2001·International Journal of STD & AIDS·A M Geretti, P Easterbrook
Mar 27, 2001·Journal of Acquired Immune Deficiency Syndromes : JAIDS·S G Deeks
Jul 13, 2001·JAMA : the Journal of the American Medical Association·D V HavlirJ K Wong
Jul 20, 2002·Journal of Acquired Immune Deficiency Syndromes : JAIDS·John Christopher WalshBrian George Gazzard
Aug 9, 2002·AIDS Research and Human Retroviruses·Jose L CasadoSantiago Moreno
Sep 28, 2002·AIDS·Gilbert GreubUNKNOWN Frankfurt HIV Clinic Cohort and the Swiss HIV Cohort Study
Oct 3, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ajay K SethiJoel E Gallant
Oct 25, 2003·Antimicrobial Agents and Chemotherapy·Katharina WolfBarbara Schmidt
Mar 27, 2004·The Journal of Antimicrobial Chemotherapy·David R BangsbergSteven G Deeks
Jan 20, 2006·The New England Journal of Medicine·Joel E GallantUNKNOWN Study 934 Group
Aug 17, 2006·AIDS Research and Human Retroviruses·M Angeles Rodríguez-ArenasUNKNOWN CoRIS-MD
Sep 13, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·John A BartlettUNKNOWN Clinically Significant Long-Term Antiretroviral Sequential Sequencing Study (CLASS) Team
May 15, 2007·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Laura E Jones, Alan S Perelson
Jul 25, 2007·The Journal of Antimicrobial Chemotherapy·Eva PovedaVincent Soriano
Mar 12, 2008·Proceedings of the National Academy of Sciences of the United States of America·Sarah PalmerMartin S King
Nov 1, 2008·The Journal of Antimicrobial Chemotherapy·Andrea KunzGundel Harms
Jun 11, 2009·JAMA : the Journal of the American Medical Association·Carl W Dieffenbach, Anthony S Fauci
Oct 27, 2009·Antiviral Research·Annemarie M J WensingMonique Nijhuis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.